Roswell Park Tests Positive for COVID-19 Patients: Lawsuit Results in Sound bites
Lawsuit: To date no one has sued the pharmaceutical company who sells a product containing the medically novel coronavirus RNA (coronavirus-RNA) gene and executed at Roswell Park Bionutics Inc (RBC) reporting any cases of patient exposure. We have filed a lawsuit in the district court stated a notice on Wednesday filed by Gizmodo Media. The attorney general of New York filed a similar lawsuit in the district court on Wednesday and the court is expected to decide the case soon.
Roswell Park manufactures and markets the product called Last Line PE a generic version of automolog 015 made by Merck Cos medicaldevice division.
This product has been marketed by other individuals and organizations including the USA Pediatric Advanced Research Alliance and the International Society of Colorectal Cancer Foundation specifically for use in patients with spinal cord injury and other painful conditions including Crohns disease ulcerative colitis and gastrointestinal cancers.
Renee Floreen a pharmacist on the unit who was not authorized to speak publicly due to concerns about her safety told Reuters that she was told that patients were being placed on either Last Line Packing List 4 or 5 as of Wednesday morning. Patients on the aforementioned lists are being evaluated for the products safety amid seniority.
Barbara Weber director of marketing and sales at Feel Well one of five suppliers told Reuters that customers may be able to purchase the product from them requiring up to 72 hours of QC. She said a record 1000 orders had come through Thursday evening and that RBC was distributing the product to more than 1600 pharmacies in the United States and Ontario.
On Wednesday the New York Attorney Generals office filed a lawsuit against RBC accusing the drugmaker of violating federal law by re-manufacturing old medicine products.
This is not a voluntary action and RBC must act quickly to prevent this type of unfair competition stated deputy attorney general Noam Bramson in a statement.
The medical-device industry is feeling the strain of generic drug expirations which the U. S. Department of Justice has blamed on the introduction of newer biosimilar therapies which are chemically similar to the original.
Many of RBCs patents on Last Line are licensed to generic drug makers such as Merck Sanofi and Eli Lilly which has made Last Line available to license to them.
Last Line is branched off from Merck which acquired RBC in 2019 for 3. 5 billion after RBC failed in its aggressive move to fill a 40 billion gap left by the rapid decline of Mercks ill-fated Pfizer Inc. Last Line began in 2016 and is expected to deliver to 40 billion by the end of 2021 that would help meet growing prescriptions in the U. S. and other developed countries.
Merck said Last Line products do not infringe upon the rights of third parties and that it is continuing to fight the patent infringement.